8 news items
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
APRE
28 May 24
, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
APRE
14 May 24
Aprea's research and development team has identified a new target in synthetic lethality. Our chemists and discovery team
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
APRE
2 May 24
acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
APRE
10 Apr 24
our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
APRE
26 Mar 24
Aprea's research and development team has identified a new target in synthetic lethality. Our
sqvc sfb0emtqaw5ullq192
APRE
11 Mar 24
products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use
gqcgog97jeppf22n1 ttlav6q77p6
APRE
11 Mar 24
ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts
k9ks5m6 v4j3m3gbmtypi42h5m0sogac9qvfze7ep
APRE
5 Mar 24
and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business
- Prev
- 1
- Next